DMYD-B:STO
Diamyd Medical AB
၁.၀၃ SEK
arrow_downward
-၁.၇၂%(-၀.၀၁၈) 1D
အောက် ၁၄, GMT+၂ ၁၇:၂၁:၂၄ · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
၁.၀၅ SEK
High
၁.၀၇ SEK
Low
၁.၀၁ SEK
Mkt. cap
၁၅.၅၇ ကုဋေ
Avg. vol.
၈.၃၂ သိန်း
Volume
၁.၇၂ သိန်း
52-wk high
၁၇.၈၈ SEK
52-wk low
၀.၉၀ SEK
EPS
-၁.၇၆ SEK
Shares outstanding
၁၃.၄၀ ကုဋေ
No. of employees
၄၂
Open
၁.၀၅ SEK
High
၁.၀၇ SEK
Low
၁.၀၁ SEK
Mkt. cap
၁၅.၅၇ ကုဋေ
Avg. vol.
၈.၃၂ သိန်း
Volume
၁.၇၂ သိန်း
52-wk high
၁၇.၈၈ SEK
52-wk low
၀.၉၀ SEK
EPS
-၁.၇၆ SEK
Shares outstanding
၁၃.၄၀ ကုဋေ
No. of employees
၄၂
News stories
From web sources and news partners
TradingView
·
ပြီးခဲ့သည့် ၅၂ မိနစ်
S&P 500 ends longest streak of calm since 2020 as AI trade sinks
MarketBeat
·
ပြီးခဲ့သည့် ၅၉ မိနစ်
CoreWeave (NASDAQ:CRWV) CRO Jonathan Jones Sells 15,811 Shares of Stock
BigGo Finance
·
ပြီးခဲ့သည့် ၄၈ မိနစ်
U.S. Inflation Surprises to the Upside, Hammering Tech Stocks and Sending Nasdaq to Multi-Month Low
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB